News
10-13-2015, 04:23 AM
In the presence of the HER2 inhibitor lapatinib, the tumor suppressor molecule FOXO changes role and desensitizes HER2+ breast cancer cells to the drug, leading to relapse.
More... (http://www.medicalnewstoday.com/articles/300879.php)
More... (http://www.medicalnewstoday.com/articles/300879.php)